Terumo Medical Corporation

terumomedical.com

Terumo Medical Corporation (TMC) was established in 1972 as a U.S. subsidiary of Tokyo-based Terumo Corporation, one of the world’s leading medical device manufacturers. TMC develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

news image

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More

Business Insights

PHASEBIO PHARMACEUTICALS TO PARTICIPATE IN THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

PhaseBio Pharmaceuticals, Inc. | February 25, 2022

news image

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual...

Read More

IMMATICS PARTNERS GSK IN DEAL WORTH €1B TO DEVELOP CANCER THERAPIES

Labiotech.eu | February 21, 2020

news image

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive €46M upfront and €509M in undisclosed developmental and commercial milestone payments per program, plus royalties. These thera...

Read More

Pharma Tech

PACE® LIFE SCIENCES ACQUIRES BIOPHARMA GLOBAL, EXPANDING FDA REGULATORY AFFAIRS STRATEGY AND CONSULTING CAPABILITIES

Pace® Life Sciences | September 09, 2022

news image

Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization and a subsidiary of Pace®, a science and technology company, announced today that it has acquired Biopharma Global. Biopharma specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs. "Pace® provides great value in our marketplace through our technic...

Read More
news image

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More
news image

Business Insights

PHASEBIO PHARMACEUTICALS TO PARTICIPATE IN THE COWEN 42ND ANNUAL HEALTH CARE CONFERENCE

PhaseBio Pharmaceuticals, Inc. | February 25, 2022

PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual...

Read More
news image

IMMATICS PARTNERS GSK IN DEAL WORTH €1B TO DEVELOP CANCER THERAPIES

Labiotech.eu | February 21, 2020

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive €46M upfront and €509M in undisclosed developmental and commercial milestone payments per program, plus royalties. These thera...

Read More
news image

Pharma Tech

PACE® LIFE SCIENCES ACQUIRES BIOPHARMA GLOBAL, EXPANDING FDA REGULATORY AFFAIRS STRATEGY AND CONSULTING CAPABILITIES

Pace® Life Sciences | September 09, 2022

Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization and a subsidiary of Pace®, a science and technology company, announced today that it has acquired Biopharma Global. Biopharma specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs. "Pace® provides great value in our marketplace through our technic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us